Featured Opinions
Back to the Future (of Pharma Sales)
by Kevin Dolgin
Kevin Dolgin looks back (and forwards) at some of his sales force predictions. Which ones came true and which are still ideas in gestation?
Make no bones about it: Treatment adherence is a challenge in Osteoporosis
It has been estimated that over 200 million people worldwide have osteoporosis and the prevalence is expected to increase as the population continues to age. For this reason, patient adherence for Osteoporosis treatment is more important than ever.
In the Eye of the Storm: Payer Value Perspective Key to Market Access
Rita E. Numerof, Ph.D delves into the topic of market access, offering a detailed study on how best to approach, and work with, payers.
by Graham Young
Graham Young applies his own unique logic to the global warming conundrum and looks at what pharma can do to help. The solution? Contraception!
by Kevin Dolgin
Kevin Dolgin explores where pharma sales forces go now in the wake of the monumental shift in budgets and attitudes the industry has been faced with in recent years...
'Mal Bernard' returns to eyeforpharma to question the ethical issues our industry faces as well as to examine what would happen to pharmaceuticals if it faced a recession-style meltdown...
Ten Hurdles to Patient Adherence
There are many factors which can influence the level of patient adherence in any given treatment, Jeanne Barnett looks at how social platforms can provide the answers and presents her findings.
Do you need an infographics strategy?
by cadelarge
Craig DeLarge examines how pharma can capitalize on yet another new media trend.
M’s the word: Youth is wasted on the young
Experience matters, wherever you’re from
The EU privacy directive: What is ‘strictly necessary’?
by Paul Cook
Paul Cook, analytics consultant with Blue Latitude, on the impact of the EU’s privacy directive on digital marketing and sales tracking
Pharma marketing: How to be ‘social’ in Brazil
Though the Internet is not quite a mass medium yet, Brazilians are very open to interacting with brands via social media
A behavior change is gonna come
Will Myddelton, user experience consultant with Blue Latitude, on the human side of behavior change
A growth opportunity for pharma: Hispanics
by EileenOBrien
When US marketing as a whole is becoming saturated, the Hispanic community offers potential growth
M’s the word: Pharma marketing, the director’s cut
Why pharma marketing is like directing a feature film
Patient engagement and oncology care
by Gena Cook
Gena Cook, CEO of Navigating Cancer, on how patient engagement can become part of an oncology practice’s care model
Pharma marketing: China’s digital discrepancy
by Grace Zhao
Treat China like China. In fact, treat all local markets as unique
M’s the word: Against assumptions
Why ‘assume’ makes an ‘ass’ out of ‘u’ and ‘me’
What pharma needs to know about the Digital Health Coalition
by EileenOBrien
How the Digital Health Coalition is furthering the discussion of digital and electronic marketing of healthcare products and services
Pharma marketing and storytelling
Want to align your brand team with your marketing plan? Tell a good story!
M’s the word: Why I believe in strategy
Even a wrong decision is better than an endless debate
The power of rare disease patients
by Wendy White
February 29 is Rare Disease Day. Time to celebrate hyper-empowered rare disease patients
M’s the Word: Down and out in Sao Paulo
There’s nothing like a field visit to give you a little perspective
Tweetchat, social media, and pharma marketing
by EileenOBrien
The biopharmaceutical marketing and social media tweetchat, #SocPharm, celebrated its second anniversary. Join the conversation!
M’s the word: Practice makes (marketing) perfect
Take a little extra time, get a more valuable result